Forbes March 21, 2025
This could end up making your wallet lighter if you are taking Ozempic or Zepbound for diabetes or weight loss. From 2024 to 2025, insurance coverage of Ozempic, which contains semaglutide, went down by 22%, based on GoodRx’s analyses of data from Managed Markets Insight and Technology. That meant an additional 1.1 million people no longer had such coverage for the most often filled glucagon-like peptide-1 receptor agonist. During that same time span, the number of people with no insurance coverage for another GLP-1 receptor agonist, Zepbound, increased by 14%, which meant that another 4.9 million or so more people were bound for no insurance coverage for the tirzepatide-containing Zepbound.
Demand For Ozempic, Zepbound And Other GLP-1 Agonists Continues To...
Today's Sponsors
Today's Sponsor